Urinary Melatonin in Relation to Postmenopausal Breast Cancer Risk According to Melatonin 1 Receptor Status

Details

• Personal Author:
  Beck AH ; Brown SB ; Devore EE ; Eliassen AH ; Hankinson SE ; Schernhammer ES ; Warner ET
• Description:
  Background: Urinary melatonin levels have been associated with a reduced risk of breast cancer in postmenopausal women, but this association might vary according to tumor melatonin 1 receptor (MT1R) expression. Methods: We conducted a nested case-control study among 1,354 postmenopausal women in the Nurses' Health Study, who were cancer free when they provided first-morning spot urine samples in 2000 to 2002; urine samples were assayed for 6-sulfatoxymelatonin (aMT6s, a major metabolite of melatonin). Five-hundred fifty-five of these women developed breast cancer before May 31, 2012, and were matched to 799 control subjects. In a subset of cases, immunohistochemistry was used to determine MT1R status of tumor tissue. We used multivariable-adjusted conditional logistic regression to estimate the relative risk (RR) of breast cancer [with 95% confidence intervals (CI)] across quartiles of creatinine-standardized urinary aMT6s level, including by MT1R subtype.Results: Higher urinary melatonin levels were suggestively associated with a lower overall risk of breast cancer (multivariable-adjusted RR = 0.78; 95% CI = 0.61-0.99, comparing quartile 4 vs. quartile 1; Ptrend = 0.08); this association was similar for invasive vs. in situ tumors (Pheterogeneity = 0.12). There was no evidence that associations differed according to MT1R status of the tumor (e.g., Pheterogeneity for overall breast cancer = 0.88).Conclusions: Higher urinary melatonin levels were associated with reduced breast cancer risk in this cohort of postmenopausal women, and the association was not modified by MT1R subtype.Impact: Urinary melatonin levels appear to predict the risk of breast cancer in postmenopausal women. However, future research should evaluate these associations with longer-term follow-up and among premenopausal women. [Description provided by NIOSH]
• Subjects:
  Aging Biomarkers Energy Metabolism Epidemiology Neoplasms Occupational Health Safety Urine Women
• Keywords:
  Age Groups Breast Cancer Cancer Humans Metabolites Sampling Tumors
• ISSN:
  1055-9965
• Document Type:
  Text
• Funding:
  Grant
• Genre:
  Journal Article
• Place as Subject:
  Massachusetts ; OSHA Region 1 ; OSHA Region 3 ; Pennsylvania
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Pages in Document:
  413-419
• Volume:
  26
• Issue:
  3
• NIOSHTIC Number:
  nn:20051030
• Citation:
  Cancer Epidemiol Biomark Prev 2017 Mar; 26(3):413-419
• Contact Point Address:
  Elizabeth E. Devore, Brigham and Women's, 181 Longwood Avenue, Boston, MA 02115
• Email:
  nheed@channing.harvard.edu
• CAS Registry Number:
  Melatonin (CAS RN 73-31-4)
• Federal Fiscal Year:
  2017
• NORA Priority Area:
  Healthcare and Social Assistance
• Performing Organization:
  Brigham and Women's Hospital, Inc., Boston, Massachusetts
• Peer Reviewed:
  True
• Start Date:
  20100801
• Source Full Name:
  Cancer Epidemiology, Biomarkers & Prevention
• End Date:
  20190831
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:60c98c8590105439442515d8638b78d8583a61833b4968715c156db7e930fbecacdf02e3cf953e686166f4ffa554252a9632320a1dda95c1ded426d3fa337373
• Download URL:
  https://stacks.cdc.gov/view/cdc/211169/cdc_211169_DS1.pdf
• File Type:
  [PDF - 228.72 KB ]